Endothelial cell leakiness is regulated by mediators such as thrombin, which promotes endothelial permeability, and anti-inflammatory agents, such as angiopoietin-1. Here we define a new pathway involved in thrombin-induced permeability that involves the atypical protein kinase C isoform, PKCζ. Chemical inhibitor studies implicated the involvement of an atypical PKC isoform in thrombin-induced permeability changes in human umbilical vein endothelial cells. Thrombin stimulation resulted in PKCζ, but not the other atypical PKC isoform, PKCλ, translocating to the membrane, an event known to be critical to enzyme activation. The involvement of PKCζ was confirmed by over-expression of constitutively active PKCζ, resulting in enhanced basal permeability. Dominant-negative PKCζ prevented the thrombin mediated effects on EC permeability and inhibited thrombin-induced activation of PKCζ. Rho activation does not appear to play a role, either up or downstream of PKCζ, as C3 transferase does not block thrombin-induced PKCζ activation and dominant-negative PKCζ does not block thrombin-induced Rho activation. Finally, we show that angiopoietin-1 inhibits thrombin-induced PKCζ activation, Rho activation and Ca ++ flux, thus demonstrating that the powerful anti-permeability action of angiopoietin-1 is mediated by its action on a number of signaling pathways induced by thrombin and implicated in permeability changes.
INTRODUCTION
One of the essential functions of the endothelial cell (EC) lining is to maintain the essentially impermeable nature of the blood vessel, controlling the passage of solutes and inflammatory cells from the circulation to the tissues. EC hyper-permeability is a characteristic of blood vessels in many pathologies, for example, newly formed micro-vessels in tumors are highly permeable. Indeed, such hyper-permeability allows the deposition of fibrin in tumors, which supports and promotes cell adhesion and migration, essential steps in the angiogenic response. 1, 2 In chronic inflammatory states such as in rheumatoid arthritis and atherosclerosis, increased transmigration of inflammatory cells across the activated endothelium is seen. A number of factors have previously been described that promote alterations in vessel integrity, for example, thrombin, 3, 4 which produces plasma leakage; tumor necrosis factor, 5, 6 which induces adhesion and transmigration of leukocytes; and vascular EC growth factor (VEGF), 2, 7 which induces cell migration and vascular hyper-permeability.
Thrombin is a potent activator of ECs and in vitro studies show that it induces phosphorylation changes in PECAM-1 and VE-Cadherin, 8 and an associated increase in the permeability of confluent EC monolayers. 3, 4 Thrombin signaling in vascular ECs is mediated by the protease-activated receptor PAR-1, a G-protein coupled receptor that can potentially activate multiple downstream signaling effectors, 9 including phospholipases, with subsequent changes in intracellular Ca ++ concentration and Ca ++ /calmodulin dependent myosin light chain kinase (MLCK) activity. Thrombin also activates the small GTPase, Rho, via PAR-1 mediated effects on the G protein, G 12/13 . The activation of Rho can also take place through a protein tyrosine kinase dependent pathway. 10, 11 Rho has multiple downstream targets, including myosin light chain (MLC) phosphatase, which regulates MLC, and which is
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PKCs are controlled by their relocalization and phosphorylation status, such that enzyme localization to the plasma membrane and enzyme phosphorylation are indicative of enzyme activation. [23] [24] [25] [26] In terms of regulation of endothelial permeability, the specific isoform of PKC involved appears to be highly dependent on species, organ, stimulant and culture conditions.
For thrombin-induced permeability changes, there have been reports dismissing the involvement of PKCs, 10 or implicating PKCα, 19, 21, 27, 28 PKCε 21 or PKCζ. 29 Angiopoietin-1 (Ang-1) is the ligand for the EC-specific tyrosine kinase receptor Tie2, 30 and both Ang-1 and Tie2 expression are essential for successful angiogenesis. Knockout of ligand or receptor leads to disrupted angiogenesis, which results from defects in the interactions between ECs and adjacent mesenchymal cells and extracellular matrix. 31, 32 The Ang-1/Tie2 axis also appears to be involved in maintaining endothelial integrity in adult vessels.
Transgenic expression of Ang-1 results in leakage-resistant blood vessels, 33 while systemic administration of Ang-1, using adenovirus mediated gene delivery, inhibited edema and vessel leakage following challenge with mustard oil or VEGF. 34 These results are complemented by in vitro studies that have shown that Ang-1 stabilizes EC networks and
For personal use only. on . by guest www.bloodjournal.org From promotes EC survival. 35 Recent studies in our laboratory have shown that Ang-1 is both an anti-permeability and anti-inflammatory agent as it reduces basal EC permeability, prevents VEGF and thrombin-stimulated EC permeability increases, and inhibits tumor necrosis factor-α-mediated transendothelial neutrophil migration. 8 Thus, Ang-1 and Tie2 signaling have an essential role, not only in vascular development, but also in vascular maintenance.
The results described herein add to our understanding of thrombin-induced permeability changes. We define another signaling pathway critical in mediating thrombin-induced permeability. Thus, together with previously reported effects of thrombin on RhoA (Rho kinase), Ca ++ flux (Ca/calmodulin) and protein tyrosine kinases, we show here that thrombin also activates the PKCζ to regulate EC permeability. Interference with any of these pathways can severely compromise EC permeability. Importantly, we demonstrate that Ang-1 inhibits EC permeability through its action on these pathways. We have shown previously that Ang-1 inhibits the potential downstream targets of the protein tyrosine kinases, the junctional proteins PECAM and VE-cadherin. 8 As we show here, Ang-1 also inhibits thrombin-induced PKCζ activation, Rho activation and Ca ++ flux.
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MATERIALS AND METHODS
Reagents. Ang-1, obtained from Regeneron Inc, was used as described. 8, 36 Bisindolylmaleimide I hydrochloride and Calphostin C were from Calbiochem Novabiochem, (Croydon, Vic, Australia). Chelerythrine chloride and H-89 were from Biomol Research Laboratories Inc, (Plymouth Meeting, PA, USA). Thrombin (from human plasma), protease inhibitor cocktail, and FITC-conjugated dextran (MW 40,000) were from Sigma-Aldrich (St.
Louis, MO, USA). Fura 2 acetoxymethyl ester (fura 2/AM) and pluronic F-127 were from Molecular Probes, (Eugene, OR, USA).
Cells and cell culture. Human umbilical vein endothelial (HUVE) cells were grown in M119 medium with 20% fetal calf serum (FCS) as described. 36 Cells were used at passage four or less. For infection with adenoviral constructs, cells were grown to 80% confluence and exposed to 2. with 0.5 mM EDTA, 0.5 mM EGTA, 10 mM β-mercaptoethanol, 5% glycerol, 2 mM NaF, 1 mM NaVO 4 and protease inhibitor cocktail). Cells were mechanically homogenized and
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From 9 centrifuged for 15 min at 1200 × g at 4 °C. The supernatant was further centrifuged for 1 hr at 125 000 × g at 4 °C. The resultant supernatant, containing the cytosolic components, was removed and the pellet, containing the membrane components, was resuspended in 0.5 ml of homogenization buffer supplemented with 0.5% Triton X100 and 100 mM NaCl. Proteins in 20 µl of each fraction were separated by SDS-PAGE, transferred to PVDF membranes and probed with the anti-PKCζ antibody, as described above.
Measurement of Ca
++ release from intracellular stores. HUVE cells were cultured to confluence on fibronectin coated coverslips. Cells were loaded with fura 2/AM by incubating the coverslips in 500 µl of Hank's medium (137 mM NaCl, 5.4 mM KCl, 0.8 mM Images were captured as described above.
Rho Activity Assay. The activation of Rho was assayed using the EZ-detect™ Rho Activation Kit (PIERCE Biotechnology, Rockford, IL, USA). HUVE cells were grown to confluence in fibronectin-coated flasks, and then starved overnight in serum free medium.
Cells were treated with Ang-1 or thrombin as required. One milligram of protein was used for each pull-down assay, following the manufacturer's protocol.
Statistics. Student's t-test.
RESULTS
Identification of PKC Isoform involved in thrombin-induced permeability
PKC activation has been linked to thrombin-induced changes in EC permeability, [14] [15] [16] [17] [18] [19] [20] [21] [22] although the results from many laboratories are far from consistent. It would appear that species, organ, stimulant and culture conditions can influence whether PKCs are involved, and if so, the relevant isoform. To clarify the role of PKC in our system and to determine the specificity of isoforms involved in thrombin-induced permeability, we took advantage of the varying specificities of PKC inhibitors. We used chelerythrine chloride, which inhibits all PKC isoforms, 39 Calphostin C, an inhibitor of classical and novel PKCs, 40 and bisindolylmaleimide I, a concentration dependent inhibitor of PKCs, 41 whereby at 100 nM it inhibits classical and novel PKC isoforms while at 6µM it inhibits all PKC isoforms. 41, 42 Using the passage of FITC-labeled dextran through monolayers of HUVE cells as a measure of permeability, we found that chelerythrine chloride at 1 µM (Fig 1A) inhibited thrombin 11 stimulated EC permeability, supporting the involvement of PKCs. Calphostin C (Fig 1B) and bisindolylmaleimide I at 100 nM (BisLo, Fig 1C) had no effect on the thrombin-induced EC permeability. However, bisindolylmaleimide I at 6 µM (BisHi, Fig 1C) inhibited the permeability change. The effects observed with both Calphostin C and low dose bisindolylmaleimide suggested that classical and novel PKCs are not involved, and the high dose bisindolylmaleimide result together with chelerythrine chloride inhibitor suggests that atypical PKC isoforms may play a role in thrombin-induced EC permeability increases seen under these experimental conditions.
Figure 1. PKC inhibitors selectively block thrombin stimulated permeability increases in ECs
Cells were untreated (Nil), treated with thrombin (0.2U/ml), (T) for 15 min, pre-treated with inhibitor for 15 min or pre-treated with inhibitor followed by thrombin. FITC-dextran passage (µg/ml) during 30 min is shown.
A. Chelerythrine chloride blocks thrombin-stimulated permeability increases in ECs (CC, 1 µM).
B. Calphostin C does not block thrombin-stimulated permeability increases in ECs (CalC, 100 nM).
C Bisindolylmaleimide I blocks thrombin-stimulated permeability increases in ECs at high concentrations (BisHi, 6µM) but not at low concentrations (BisLo, 100 nM).
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The two atypical PKC isoforms, PKCζ and PKCλ, are present in ECs. 43 Since PKCs typically translocate to the membrane upon activation, we used translocation as an indicator as to whether these isoforms are involved in thrombin-mediated permeability changes. 44, 45 Confluent quiescent ECs were stained with anti-PKCζ and anti-PKCλ antibodies. Both PKCζ and PKCλ were distributed throughout the cytoplasm (Fig 2A a and c) . The confluence of the ECs was confirmed by counter-staining for the junctional protein VE-cadherin (Fig 2A b and   d ). When these cells were treated with thrombin, PKCζ underwent redistribution (Fig 2B c) ,
while PKCλ (Fig 2B a) remained evenly distributed despite significant contraction of individual cells, VE-cadherin staining is shown in figure 2B b and d. The cell contraction and the formation of gaps became evident with extended treatment with thrombin, as has been reported previously. 10, 12 Cells with and without thrombin treatment were also stained for PKCα and PKCε, since these two isoforms have been linked to thrombin-induced activation. 19, 21, 22, 27, 28 PKCα displayed a similar diffuse staining pattern to PKCζ, and thrombin did not cause any relocalization (Fig 2C a and b) . PKCε displayed nuclear staining, as previously reported, 29 and there was no clear relocalization with thrombin treatment, even though there was obvious cell retraction ( Fig 2C c and d) . These results support our inhibitor studies, suggesting that classical and novel isoforms PKC do not play a major role in thrombin-induced permeability changes in our system. Targeting of PKC isoforms to the membrane typically occurs upon enzyme activation, 23 and the translocation of PKCζ in thrombin induced permeability was confirmed by cell fractionation studies. The results shown in figure 2D indicate enrichment of PKCζ in the membrane fraction after thrombin treatment.
For 
Activation of PKC] increases the permeability of EC
To confirm that PKCζ is a mediator of thrombin-stimulated increases in EC permeability, wild-type, dominant-negative and constitutively active PKCζ were over-expressed in EC by infection with adenoviruses carrying these constructs. Dominant-negative PKCζ has the critical threonine of the activation-loop, at position 410, mutated to alanine. 37 Constitutively active PKCζ results from fusion of the amino-terminal myristoylation sequence of p60 c-Src to the amino terminus of PKCζ, thereby constitutively targeting the resultant protein to the cell membrane. 37 When cells over-expressing wild-type PKCζ were tested for permeability, they responded to thrombin in a similar way to cells infected with the empty vector (Fig 3A) ,
indicating that over-expression of this isoform per se does not alter the permeability of the cells or their response to thrombin. Infection of ECs with adenovirus carrying dominantnegative PKCζ resulted in a slight decrease in the basal permeability in those lines tested, which may indicate that the mutant is able to inhibit some of the basal activity attributed to
PKCζ. The dominant-negative PKCζ mutant was able to significantly inhibit the thrombinstimulated increase in EC permeability when compared with cells infected with empty vector (Fig 3B) . Conversely, ECs infected with adenovirus carrying constitutively active PKCζ were highly permeable, even in the absence of thrombin. When cells infected with the constitutively active PKCζ construct were stimulated with a maximal dose of thrombin (approximately 1 U/ml for 15 minutes), there was a 40% increase in permeability compared to the basal permeability (data not shown), indicating that thrombin is able to promote permeability over and above that seen in the presence of constitutively active PKCζ expression. 
Angiopoietin-1 inhibits thrombin-induced relocalization and phosphorylation of PKC] in EC
As we have reported previously, Ang-1 is a potent inhibitor of thrombin-induced permeability 8 ( Fig 4A) . It is also able to inhibit basal permeability, which is consistent with Ang-1 inhibiting basal EC activation. We therefore investigated whether the Ang-1 had an effect on PKCζ activation.
Staining of confluent quiescent ECs with the anti-PKCζ antibody showed PKCζ to be distributed throughout the cytoplasm (Fig 4B a) , and thrombin stimulation caused PKCζ to be localized to the cell membrane (Fig 4B b) . When ECs were pre-treated with Ang-1 at 0.1 µg/ml for 30 minutes (Fig 4B c) A. Ang-1 inhibits thrombin stimulated EC permeability increases. Cells were untreated (Nil), treated with Ang-1 (0.1 µg/ml)(Ang-1) for 30 min, treated with thrombin (0.2U/ml)(T) for 15 min, or pre-treated with Ang-1 (0.1 µg/ml) for 30 min followed by thrombin (Ang-1 + T). 
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To confirm the Ang-1 effect to inhibit PKCζ activation, another indicator of activation, the phosphorylation status of PKCζ was investigated. Phosphorylation of the threonine in the activation-loop of PKCs is the critical first step of PKC activation. This is rapidly followed by autophosphorylation of a threonine and a serine residue within the catalytic domain and concomitant translocation from the cytoplasm to the cell membrane. 23 (Fig 4C) . In cells overexpressing wild-type PKCζ, thrombin treatment for 15 minutes increased the phosphorylation of PKCζ (Fig 4D) , while pretreatment with Ang-1 at 0.1 µg/ml for 30 minutes or bisindolylmaleimide I at 6µM for 15 minutes inhibited thrombin-stimulated PKCζ phosphorylation (Fig 4D) . Thus, thrombin stimulates PKCζ activation (phosphorylation and translocation), and Ang-1 inhibits activation. Cell contraction and shape change are dependent on actin reorganization, which can be regulated by the small GTPase Rho. 10, 11, 28 Unstimulated cells displayed a cortical actin-type staining (Fig 5A a) . Thrombin induced the classic pattern of stress fiber formation (Fig 5A b) , which was inhibited by Ang-1 (Fig 5A c) , showing the typical cortical actin-type staining pattern seen in untreated EC (Fig 5A a) , a characteristic of an intact impermeable monolayer. 10, 13 Consistent with these actin-based changes, Ang-1 also inhibited thrombininduced activation of Rho (Fig 5B) , as measured in pull-down assays. In the three experiments performed, Ang-1 induced a 40%-60% inhibition of the active Rho compared to thrombin alone.
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Thrombin-induced activation of PAR-1, among other events, raises intracellular Ca ++ concentration through mobilization of Ca ++ from intracellular stores, and this increase in intracellular Ca ++ controls the activity of the Ca ++ /calmodulin dependent MLCK which also affects the actin based cytoskeletal machinery. 46 To determine whether Ang-1 affects this arm of thrombin signaling, the thrombin-induced Ca ++ flux was measured in fura 2 loaded ECs in the presence or absence of Ang-1. Ang-1 at 0.1 µg/ml was used as we have previously demonstrated that this is optimal for inhibition of thrombin-induced permeability. Figure 5C shows that the Ang-1 significantly inhibited the thrombin-induced Ca ++ flux.
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C. Cells were loaded with fura 2 either in the absence or presence of Ang-1 (0.1 µg/ml) for 60 min. Cells were then treated with thrombin (0.2 U/ml) and fluorescence measured. The pooled results, expressed as fluorescence ratio, are given for 100 cells from each of three experiments.
Rho activation pathways are not involved in thrombin-induced permeability changes through PKC]
Since there are reports that Rho and PKCζ are able to regulate the activity of each other, 42, 47 we first sought to determine whether Rho is a downstream target for PKCζ. The results in figure 6A show that the dominant-negative PKCζ does not block thrombin-induced Rho activation nor does constitutively active PKCζ regulate basal Rho activity. When cells expressing constitutively active or dominant-negative PKCζ were stained for actin stress fiber formation, no alteration from basal unstimulated cells was observed (data not shown).
To determine whether PKCζ is regulated by Rho in our system, we used the specific Rho inhibitor Clostridium botulinum C3 transferase. Although this inhibitor totally blocked thrombin-induced actin cytoskeleton reorganization (data not shown), it had no effect on thrombin-induced PKCζ phosphorylation (Fig 6B) , suggesting that Rho was not involved in PKCζ activation.
For both of which result in MLCK activation, have been firmly linked to permeability increases mediated through changes in the actin cytoskeleton. Our data described herein identifies a new pathway involving the atypical PKC isoform, PKCζ, in the regulation of thrombininduced EC leakiness. We have previously shown that the vasculogenic factor Ang-1 inhibits thrombin-induced permeability increases. 8 Our results here show that Ang-1 achieves its inhibition of EC permeability by acting on the above thrombin-stimulated pathways linked to permeability, that is, Ang-1 inhibits Ca ++ flux, inhibits Rho activation and inhibits activation of PKCζ. These results add to our previous findings, 8 where we showed that Ang-1 also acts to inhibit the thrombin-induced tyrosine phosphorylation of VE-cadherin and PECAM-1, 8 suggesting stabilization of the EC junctions by Ang-1.
Thrombin is a serine protease with multiple roles central to vascular biology, acting upon platelets, ECs and circulating clotting factors. 48 Thrombin is a potent activator of ECs, increasing intercellular gap formation and the permeability of confluent EC monolayers. 4, 14 Thrombin signaling is mediated by the protease-activated receptor PAR-1 9 . PAR-1 can activate a number of downstream signaling pathways, with the molecules activated depending upon the G-proteins recruited to the receptor, with PKC shown to be one such downstream intermediate. 48 In HUVE cells, all PKC classes are represented, with the classical isoform PKCα, the novel isoform PKCε and the atypical isoform PKCζ predominating. 43, 49 Previous In an attempt to determine the mechanism of PKCζ dependent control of permeability, we reasoned that Rho was a likely downstream target of PKCζ. However, we show that PKCζ activation by thrombin resulting in permeability changes does not involve Rho, acting either up or downstream of PKCζ (Fig 6) . This is interesting given that chemoattractant-induced leukocyte adhesion and chemotaxis is mediated through Rho dependent activation of PKCζ. 39 In addition, the Ras mediated activation of NIH-3T3 cells, which results in profound disassembly of actin stress fibers, acts through Rac dependent activation of PKCζ. 42 How then does PKCζ regulate EC permeability? The identification of downstream effectors of PKCζ will help to answer this question. One possibility is that PKCζ directly associates with and phosphorylates junctional adhesion molecules such as PECAM, which is important in EC integrity and is known to be altered in both localization and phosphorylation status following thrombin stimulation. Indeed, serine/threonine phosphorylation of PECAM is important for its function, for its association with proteins such as γ catenin, and for its localization. 54 However, our initial experiments have not shown any physical association between PKCζ and
PECAM. An alternative possibility is that PKCζ may be in complexes with proteins such as PAR3. In epithelial cells atypical PKCs are known to associate in a PAR3/PAR6/aPKC complex, which localizes to tight junctions and regulates cell polarity. [55] [56] [57] [58] PAR3 also associates directly with the junctional adhesion molecule JAM. 59, 60 In EC, JAM-2, which is localized at intercellular contacts, promotes leukocyte transendothelial cell migration, 61 a process which, like altered cell permeability, involves junctional alteration.
In terms of the activation of the endothelium, it is interesting to note that PKCζ may be an important pivot for regulation of the inflammatory response. PKCζ is involved in TNF induced ICAM-1 gene transcription 62 through NF-κB activation. More recently, it has been shown that PKCζ is involved in the protein-synthesis-independent activation of ICAM-1, resulting in the early onset enhanced neutrophil adhesion to ECs. This activation occurs via PKCζ dependent phosphorylation of ICAM-1. 63 Furthermore, Ras induced transcriptional activation of VEGF synthesis is through PKCζ. 47 Thus, PKCζ is involved in permeability changes as shown here, in leukocyte adhesion and in angiogenesis, all of which are important aspects of inflammation.
Ang-1 is a powerful anti-inflammatory, anti-permeability agent, 8 as well as mediating vascular EC survival and angiogenic properties. 28, 32 Ang-1 signals via the protein tyrosine kinase receptor Tie2 through a phosphoinositide 3-kinase (PI3K)-AKT dependent pathway to mediate its pro-survival activity. The PI3K pathway leading to the generation of endothelial NO is involved in the angiogenic response to Ang-1. 64 A recent report shows that Tie2 can bind ABIN-2, the A20 binding inhibitor that is involved in inhibition of the NF-κB dependent inflammatory response in ECs. 65 that the anti-inflammatory, anti-angiogenic properties of Ang-1 are broad and play a key role in vascular control. Therefore, the signals emanating from receptor-ligand interaction are likely to be many and varied, and their elucidation awaits further investigation.
